Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 348

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 348
---
 $             | 0.09 |   |     | $           | 4.90 |   |
| Tranche 1 trigger price |     | $             | 1.25 |   |     | $           | 3.20 |   |
| Tranche 2 trigger price |     | $             | 1.50 |   |     | $           | 3.85 |   |
| Contractual term        |     |               |  3.4 |   |     |             |  4.0 |   |
| Volatility              |     |               |   90 | % |     |             |   90 | % |
| Risk-free interest rate |     |               | 3.52 | % |     |             | 4.20 | % |

At September 30, 2024 for the Successor and December 31,
2023 for the Predecessor, the fair value of derivative liabilities were classified as follows:

The classification of the fair value of derivative
liabilities and the change in the fair value measurement using significant inputs (Level 3) for the period from December 31, 2022
through September 30, 2023 and December 31, 2023 through February 14, 2024 for Predecessor and February 14, 2024 through September 30,
2024 for the Company is presented below:

| Preferred stock warrant liability (Predecessor): |     | Level 1 |   |     | Level 2 |   |     | Level 3 |            |   |     | Total |            |   |
|:-------------------------------------------------|:----|:--------|:--|:----|:--------|:--|:----|:--------|-----------:|:--|:----|:------|-----------:|:--|
| Balance at January 1, 2024                       |     | $       | - |     | $       | - |     | $       |    320,117 |   |     | $     |    320,117 |   |
| Reclassification of warrant liability to equity  |     |         | - |     |         | - |     |         |   (320,117 | ) |     |       |   (320,117 | ) |
| Balance at February 13, 2024                     |     |         | - |     |         | - |     |